Keyword: Bristol-Myers Squibb
After a jury ordered Gilead's Kite Pharma to pay $752 million for CAR-T patent infringement, BMS is asking for punitive damages in that amount, too.
The legacy Bristol-Myers business had some hematology expertise of its own—and that’s something Celgene is already taking advantage of.
BMS has been waiting years to get a crack at the previously untreated NSCLC market, but the end to its waiting may finally be in sight.
Amgen aims to prove its $13.4 billion Otezla pickup was worth it by revving up new indications and new international launches.
With BMS' Celgene deal recently closed, CEO Giovanni Caforio says he feels “even better about our opportunity” then he did when Bristol unveiled it.
While we haven't seen anything like last year's megamerger so far in 2020, EY predicts M&A will remain strong this year.
Celgene last year inked a $55 million settlement over allegations it blocked multiple myeloma drug competition. Now, it's backing out.
Tidying up business left from last year, Bristol-Myers Squibb has completed the sale of an old-school operation in Italy.
With tens of billions of dollars in revenue each year, the largest publicly traded U.S. pharmaceutical companies answer drug-pricing critics by pointing to their hefty investments in research and development. But they answer to some of the most powerful institutional investors, too—and those shareholders reaped rich rewards in 2019.